OBIO

NASDAQ Healthcare

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Biotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

๐Ÿ“Š Market Data
Price$6.08
Volume1,137,342
Market Cap365.44M
Beta0.530
RSI (14-Day)61.7
200-Day MA$4.31
50-Day MA$4.65
52-Week High$6.30
52-Week Low$2.20
Forward P/E-4.03
Price / Book18.94
๐ŸŽฏ Investment Strategy Scores

OBIO scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
High growth potential (high beta + oversold)
Contrarian plays (oversold + below moving average)
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (88/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿ”ช Falling Knife (5/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find OBIO in your text

Paste any article, transcript, or post โ€” the tool will extract OBIO and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.